Newsroom | 5932 results

Sorted by: Latest

Optical
-

Resumen: Epitech Group y Horus Pharma firman un acuerdo de licencia a escala mundial para el desarrollo del adelmidrol en el ámbito de la salud ocular

NIZA, Francia--(BUSINESS WIRE)--Epitech Group S.p.A., sociedad biofarmacéutica italiana especializada en neuroinflamación, y Horus Pharma, laboratorio francés especializado en oftalmología, anuncian un acuerdo de licencia a escala mundial sobre el adelmidrol, una molécula de la familia de las ALIAmidas desarrollada por Epitech Group. Este acuerdo otorga a Horus Pharma los derechos exclusivos de desarrollo y comercialización del adelmidrol para aplicaciones en oftalmología humana y dermatología...
-

Epitech Group and Horus Pharma sign a global licensing agreement to develop adelmidrol in eye health

NICE, France--(BUSINESS WIRE)--Epitech Group S.p.A., an Italian biopharmaceutical firm specializing in neuro-inflammation, and Horus Pharma, a French laboratory specializing in ophthalmology, announce a global licensing agreement for adelmidrol, a molecule belonging to the ALIAmide family, developed by Epitech Group. This agreement grants Horus Pharma exclusive rights to develop and market adelmidrol for human ophthalmology and periocular dermatology applications. It aims to explore new approac...
-

Tenpoint Therapeutics Announces New Drug Submission to Health Canada for the Treatment of Blurry Close-Up Vision (Presbyopia) in Adults

LONDON & WARREN, N.J.--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve vision in the aging eye, today announced a New Drug Submission (NDS) to Health Canada for the review and approval of YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% – a once-daily, dual-agent (combination) eye drop – for the treatment of presbyopia in adults. Presbyopia is the gradual lo...
-

Epitech Group et Horus Pharma signent un accord mondial de licence pour développer l’adelmidrol en santé oculaire

NICE, France--(BUSINESS WIRE)--Epitech Group S.p.A., société biopharmaceutique italienne spécialisée dans la neuro-inflammation, et Horus Pharma, laboratoire français spécialisé en ophtalmologie, annoncent un accord mondial de licence portant sur l’adelmidrol, molécule de la famille des ALIAmides développée par Epitech Group. Cet accord confère à Horus Pharma les droits exclusifs de développement et de commercialisation de l’adelmidrol pour des applications en ophtalmologie humaine et en dermat...
-

Bausch + Lomb Reports Phase 2 Findings for BL1332 in Post-Surgical Ocular Pain

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced topline results from a Phase 2 study evaluating BL1332, a first-in-class topical TRPV1 antagonist, in patients experiencing pain following photorefractive keratectomy (PRK) surgery. “What stands out from this study is the consistency of the findings,” said Yehia Hashad, MD, executive vice president, R&D and...
-

eClinicalWorks and healow Genie Manage 80% of Patient Calls at CalRetinaMD Ophthalmic Consultants

WESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, one of the largest ambulatory cloud EHRs, today announced that CalRetinaMD Ophthalmic Consultants, an ophthalmology practice based in California, is utilizing healow Genie™, an AI-powered contact center solution, to streamline patient communications and improve operational efficiency. Since implementation, healow Genie has successfully handled 80% of interactions while maintaining high-quality patient engagement. The AI contact center also s...
-

Nanoscope Therapeutics Partners with Uniphar to Expand Access to MOGENRY® Across the Gulf Cooperation Council Region

DALLAS & DUBLIN--(BUSINESS WIRE)--Nanoscope Therapeutics, Inc. (“Nanoscope”), a biotechnology company committed to developing and commercializing novel, disease-agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that it has entered into an agreement with Uniphar, a global healthcare services partner to the pharmaceutical, biotech and medtech industries, under which Uniphar will serve as Nanoscope’s exclusive named patient s...
-

Emmecell Announces First Patient Dosed in EMERALD Study of Magnetic Cell Therapy for Corneal Endothelial Disease

MENLO PARK, Calif.--(BUSINESS WIRE)--Emmecell Announces First Patient Dosed in EMERALD Study of Magnetic Cell Therapy for Corneal Endothelial Disease...
-

Octant Appoints Eddy Anglade, M.D., as Chief Medical Officer

EMERYVILLE, Calif.--(BUSINESS WIRE)--Octant, Inc., a clinical-stage drug discovery company developing corrector therapies for protein misfolding diseases, today announced the appointment of Eddy Anglade, M.D., as its first Chief Medical Officer. Dr. Anglade will lead Octant’s clinical development strategy, including advancing its lead program, OCT-980 for rhodopsin-associated autosomal dominant retinitis pigmentosa (RHO-adRP). “OCT-980 is the first molecule from our platform to reach patients,...
-

Eyeon Focus AI Near-Infrared Smart Glasses Fight Nearsightedness and Promote Eye Health

AMSTERDAM--(BUSINESS WIRE)--Eyeon Medtech introduces Eyeon Focus, AI near-infrared light-enabled smart glasses to address the growing global myopia challenge...